In Acular Patent Feud, Apotex Suffers Blow

Law360, New York (June 5, 2006, 12:00 AM EDT) -- In the latest setback for Canadian generic drug maker Apotex Inc. in its battle to market a generic version of leading itchy eye treatment Acular, a federal court has ruled that the company infringed on a patent held by Allergan Inc. and Syntex LLC, barring Apotex from filing a new drug application before the patent expires in 2009.

Late last week, the U.S. District Court for the Northern District of California ruled that Apotex and Novex Pharma, generic makers that have sought to market generic versions...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.